Phase 1b APEX study: a first in human study of KSI-101 in patients with DME End of Study Subjects with DME (n=12) Weeks 0 4 8 12 16 20 24 2.5 mg 5 mg 10 mg 66 KSI-101 injection Key inclusion criteria • Treatment-naive center-involving DME • OCT CST of ≥400 and ≤650 microns • BCVA score ≤75 and ≥25 (20/32 to 20/320 Snellen equivalent) Enrollment completed